New Preliminary Results Highlight LM® LLLT's Effectiveness in Managing DED and IOP in Glaucomatous Patients

Espansione Group is pleased to announce new and promising preliminary results demonstrating the effectiveness of LM® LLLT (Light Modulation® Low-Level Light Therapy) in managing Dry Eye Disease (DED) and Intraocular Pressure (IOP) in patients with glaucoma. These findings, recently presented at ESCRS 2024, originate from two separate clinical trials conducted by leading ophthalmologists: Prof. M. A. Teus (Spain) and the joint research team of Prof. G. Giannaccare (Italy) and Dr. C. Sannace (Italy).

Dry Eye in Glaucoma Patients: Prevalence, Incidence, and Challenges

Glaucoma is a progressive optic neuropathy and a leading cause of irreversible blindness worldwide. The management of glaucoma frequently involves chronic use of topical medications, such as prostaglandin analogs, which can lead to drug-induced iatrogenic DED.

According to recent studies, the prevalence of DED in glaucomatous patients ranges from 40% to 59%, with incidence increasing with the duration and complexity of glaucoma treatment regimens.

Patients with glaucoma and concurrent DED face unique challenges, including reduced adherence to treatment, decreased quality of life, and compromised visual outcomes. Managing DED effectively in these patients is crucial to optimizing both their ocular surface health and glaucoma therapy compliance.

Study Overview and Results—Prof. G. Giannaccare (Italy) & Dr. C. Sannace (Italy)

A prospective, randomized controlled clinical trial conducted by Prof. G. Giannaccare and Dr. C. Sannace in Italy assessed the effectiveness of LM® LLLT for managing DED in patients with glaucoma. The study included 40 eyes from 20 patients, who received LM® LLLT treatments twice weekly over three weeks. Key outcomes were measured before treatment initiation (T0) and four weeks after the final session (T1).

Key Outcomes

Statistically significant improvement in OSDI (Ocular Surface Disease Index) score and Tear Break-Up Time (TBUT)
Improvement in corneal staining, as measured by the Oxford Scale
Statistically significant improvement in the Glaucoma Symptom Scale (GSS), signaling an enhancement of overall patient comfort and visual function

Study Overview and Results—Prof. M. A. Teus (Spain)

In a separate prospective interventional study, Prof. M. A. Teus (Spain) evaluated the impact of LM® LLLT on the quality of life and ocular health of glaucoma patients undergoing chronic prostaglandin therapy. The study was accepted as an abstract during ESCRS 24. The trial included 35 eyes from 18 patients, with assessments conducted at baseline, one month, and three months post-treatment.

Key Outcomes

Statistically significant improvement in OSDI scores at both one and three-month follow-ups
Reduction in ocular redness, contributing to enhanced patient comfort
A decrease in average GAT-IOP (Goldmann Applanation Tonometry-Intraocular Pressure) from 14.29 mmHg at baseline to 12.96 mmHg at one-month follow-up, a reduction sustained at three months

In Short

These preliminary results position LM® LLLT as a valuable tool in the management of dry eye symptoms
and intraocular pressure in patients with glaucoma, potentially transforming current therapeutic approaches and opening new avenues for patient care.

ABOUT ESPANSIONE GROUP

Espansione Group is an established player in the MedTech industry. Since 1981, Espansione Group has delivered the highest standard in the industry. Every day, the company invests heavily in researching and developing the Espansione Ecosystem to achieve its ambition: establishing new paradigms in ophthalmology and beyond, driven by its desire to provide its partners and their patients with the best, certified medical technologies, Light Modulation® Low-level Light Therapy (LM® LLLT) and Optimal Power Energy® Intense Pulsed Light (OPE® IPL). Present in over 50 countries, Espansione Group aims to continue its strong growth in years to come, relentlessly focusing its efforts on research, development, and customer excellence.    

For more information, see www.espansionegroup.it

Media Contacts:

 Download: Press Release

> Back to Newsroom

Get Started Now

Get in touch to find out how you can benefit from the Espansione Ecosystem of Technologies and Solutions.

> Get Started